Why the study?
Does prasugrel reduce procedural thromboembolic and hemorrhagic complications compared to clopidogrel in patients undergoing stent-assisted coil embolization of unruptured intracranial aneurysms?
Does prasugrel reduce procedural thromboembolic and hemorrhagic complications compared to clopidogrel in patients undergoing stent-assisted coil embolization of unruptured intracranial aneurysms?
Prasugrel may reduce the clinical consequences of thromboembolic complications without increasing hemorrhagic events compared to clopidogrel in patients undergoing stent-assisted coiling of unruptured intracranial aneurysms.
No takes yet. Share an insight, caveat, or question.
May reduce thromboembolic risk in clopidogrel nonresponders; leaves open confirmation in randomized neurointerventional trials.
Sédat et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: